Les structures académiques peuvent-elles permettre une amélioration de l’accessibilité aux CAR-T cells ?
Bulletin du Cancer · 2024
DOI: 10.1016/j.bulcan.2023.10.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bulletin du Cancer, 2024. Verfasst von Camille Le Guen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France. Electronic address: camille.leguen@chu-nantes.fr. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
In France, hospital cell therapy units have not been authorised to routinely produce chimeric antigen receptor T lymphocytes (CAR-T cells), which would then be referred to as academic CAR-T cells. CAR-T cells are classified as advanced therapy medicinal products and correspond to genetically modified T lymphocytes ex vivo. The CAR-T cell production process is complex and requires scientific and technical expertise to meet the acceptance criteria of the pharmaceutical quality system. The most commonly used method for genetically modifying T lymphocytes is viral transduction (lentiviral or retroviral), which requires prior access to a batch of good manufacturing practice (GMP) grade viral vector. Because of its cost, this reagent is the main limiting factor for developing CAR-T cells. A CAR-T cell produced by an industrial company is expensive (around €350,000 per injection) and the time taken by the manufacturer to make it available to the clinician can vary from three to five weeks. By meeting the economic and ecological challenges, can academic structures improve access to CAR-T cells? In this article, we present the elements necessary for the feasibility of setting up CAR-T cell production in an academic structure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France. Electronic address: camille.leguen@chu-nantes.fr.
- Unité d'oncologie pédiatrique, CHU de Nantes, 44093 Nantes, France; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44000 Nantes, France.
- Unité d'oncologie pédiatrique, CHU de Nantes, 44093 Nantes, France.
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France.
- Unité d'hématologie biologique, CHU de Nantes, 44093 Nantes, France.
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44000 Nantes, France.
Zitieren
APA
Le Guen, C., Grain, A., Le Calvez, B., Saiagh, S., Vrignaud, F., Eveillard, M., Clémenceau, B., & Zahar, M. B. (2024). Les structures académiques peuvent-elles permettre une amélioration de l’accessibilité aux CAR-T cells ?. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2023.10.005
Vancouver
Le Guen C, Grain A, Le Calvez B, Saiagh S, Vrignaud F, Eveillard M, et al. Les structures académiques peuvent-elles permettre une amélioration de l’accessibilité aux CAR-T cells ?. Bulletin du Cancer. 2024. doi:10.1016/j.bulcan.2023.10.005
BibTeX
@article{LeGuen2024,
author = {Le Guen, Camille and Grain, Audrey and Le Calvez, Baptiste and Saiagh, Soraya and Vrignaud, Florence and Eveillard, Marion and Clémenceau, Béatrice and Zahar, Mina Benjelloun},
title = {Les structures académiques peuvent-elles permettre une amélioration de l’accessibilité aux CAR-T cells ?},
journal = {Bulletin du Cancer},
year = {2024},
doi = {10.1016/j.bulcan.2023.10.005}
}
EUVIMED